Ticagrelor is an oral direct-acting antiplatelet agent that inhibits P2Y12 receptor activation. The PLATO study showed that ticagrelor significantly reduced the composite outcome of vascular death, myocardial infarction (MI) or stroke compared to clopidogrel in patients with acute coronary syndrome (ACS) [1]. Post hoc analysis of the PLATO study demonstrated a lower mortality rate of pneumonia and sepsis in the ticagrelor group [2]. Moreover, a recent study found that ticagrelor possessed direct bactericidal activity against gram positive cocci (GPC) [3].
